Population pharmacokinetic modeling of MEDI8897, an extended half-life monoclonal antibody (mAb), and dose prediction in preterm and full-term infants to prevent lower respiratory tract infection due to respiratory syncytial virus (RSV)

Pierre Vadryn; Griffin M. Pamela; Shoemaker Kathryn; Takas Therese; Tatipalli Manasa; Song Xuyang; Narwal Rajesh; Khan Anis A.

首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >Population pharmacokinetic modeling of MEDI8897, an extended half-life monoclonal antibody (mAb), and dose prediction in preterm and full-term infants to prevent lower respiratory tract infection due to respiratory syncytial virus (RSV)

【24h】

Population pharmacokinetic modeling of MEDI8897, an extended half-life monoclonal antibody (mAb), and dose prediction in preterm and full-term infants to prevent lower respiratory tract infection due to respiratory syncytial virus (RSV)

机译：Medi8897的人口药代动力学建模，延长半衰期单克隆抗体（MAB），以及预料和全初期婴儿的剂量预测，以防止呼吸合胞病毒（RSV）引起的呼吸道感染

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of pharmacokinetics and pharmacodynamics》 |2018年第suppla期|共1页
作者
Pierre Vadryn; Griffin M. Pamela; Shoemaker Kathryn; Takas Therese; Tatipalli Manasa; Song Xuyang; Narwal Rajesh; Khan Anis A.;
展开▼
作者单位

MedImmune Gaithersburg MD USA;

MedImmune Gaithersburg MD USA;

MedImmune Gaithersburg MD USA;

MedImmune Gaithersburg MD USA;

MedImmune Gaithersburg MD USA;

MedImmune Gaithersburg MD USA;

MedImmune Gaithersburg MD USA;

MedImmune Gaithersburg MD USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词

相似文献

外文文献
专利

1. Population pharmacokinetic modeling of MEDI8897, an extended half-life monoclonal antibody (mAb), and dose prediction in preterm and full-term infants to prevent lower respiratory tract infection due to respiratory syncytial virus (RSV) [J] . Pierre Vadryn, Griffin M. Pamela, Shoemaker Kathryn, Journal of pharmacokinetics and pharmacodynamics . 2018,第Suppla期

机译：Medi8897的人口药代动力学建模，延长半衰期单克隆抗体（MAB），以及预料和全初期婴儿的剂量预测，以防止呼吸合胞病毒（RSV）引起的呼吸道感染
2. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants [J] . Domachowske Joseph B., Khan Anis A., Esser Mark T., The Pediatric infectious disease journal . 2018,第9期

机译：Medi8897的安全性，耐受性和药代动力学，延伸半衰期单剂量呼吸合胞病毒预防F靶向单克隆抗体作为单剂量给健康的早产儿
3. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants [J] . Domachowske Joseph B., Khan Anis A., Esser Mark T., The Pediatric infectious disease journal . 2018,第9期

机译：Medi8897的安全性，耐受性和药代动力学，延伸半衰期单剂量呼吸合胞病毒预防F靶向单克隆抗体作为单剂量给健康的早产儿
4. CHARACTERIZATION OF THE EPITOPE FOR ANTI HUMAN RESPIRATORY SYNCYTIAL VIRUS F PROTEIN MONOCLONAL ANTIBODY 101F USING SYNTHETIC PEPTIDES AND RECOMBINANT F PROTEIN MUTANTS [C] . Marian Kruszynski, Sheng Jiun Wu, Albert Schmidt the European Peptide Symposium . 2007

机译：用合成肽和重组F蛋白突变体表征抗人呼吸道合胞病毒F蛋白单克隆抗体101f的表位
5. Reovirus 1/L and influenza A infection of the upper and lower respiratory tracts: A paradigm for studies of the respiratory tract in the context of mucosal immunity. [D] . Thompson, Amy Hodson. 1998

机译：呼肠孤病毒1 / L和上下呼吸道的甲型流感感染：在粘膜免疫的背景下研究呼吸道的范例。
6. Safety Tolerability and Pharmacokinetics of MEDI8897 an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants [O] . Joseph B. Domachowske, Anis A. Khan, Mark T. Esser, -1

机译：MEDI8897的安全性耐受性和药代动力学这是一种延长剂量的针对健康早产婴儿的半衰期单剂量呼吸道合胞病毒预融合F靶向单克隆抗体
7. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants [O] . Joseph B. Domachowske, Anis A. Khan, Mark T. Esser, 2018

机译：Medi8897的安全性，耐受性和药代动力学，延伸半衰期单剂量呼吸合胞病毒预防F靶向单克隆抗体作为单剂量给健康早产儿

Population pharmacokinetic modeling of MEDI8897, an extended half-life monoclonal antibody (mAb), and dose prediction in preterm and full-term infants to prevent lower respiratory tract infection due to respiratory syncytial virus (RSV)

著录项

相似文献

相关主题

期刊订阅